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Introduction: Antibodies against mutated citrullinated vimentin (AMCV) represent a useful diagnostic marker
with correlation to disease activity in patients with rheumatoid arthritis (RA). Since seropositivity for citrullinated
autoantibodies was predictive for response to B-cell depleting therapy (BCDT) with rituximab (RTX), we investigated
whether differences in antibody fine reactivity and immunoglobulin (Ig) isotype kinetics among AMCV-positive
patients could provide additional information about outcome.
Methods: A total of 50 AMCV IgG-positive RA patients (RTX responders (RRs) n = 37 and non-responders (NRRs)
n = 13) were analyzed for reactivity against MCV epitopes and co-existent AMCV isotypes IgM and IgA. Antibody
titers were determined by enzyme-linked immunosorbent assay at baseline and 24 weeks after the first cycle of
RTX, and compared to kinetics of rheumatoid factor (RF) and antibodies against cyclic citrullinated peptide (ACCP).
Results: Recognized MCV epitopes by AMCV IgG of RRs and NRRs showed similar baseline patterns, with reducing
reactivity in RRs and unchanged or even expanding reactivity in NRRs upon RTX treatment. At baseline, RRs were
more frequently negative for AMCV subtypes, especially for IgA (68 %), compared to NRRs (31 %). Being AMCV
IgA-negative at baseline indicated a good treatment response to RTX (negative predictive value = 0.86). Co-existence
of AMCV IgA and IgG with stable titers upon treatment were associated with poorer responses to RTX. Furthermore,
reductions of AMCV IgA levels upon RTX correlated with the improvement of 28-joint Disease Activity Score (DAS28).
In comparison, subtypes of RF and ACCP were not of additional value for prediction of RTX response.
Conclusions: Restrictive IgG seropositivity against MCV with treatment-associated decline in fine reactivity and titers
was predictive for response to RTX. Double-positivity for AMCV IgG and IgA was associated with failure to respond to
BCDT, suggesting a pathogenetic and less sensitive IgA-producing B-cell subset in NRRs.Introduction
Rheumatoid arthritis (RA) is one of the most common
systemic autoimmune diseases worldwide, characterized
by chronic and erosive arthritis, as well as by an in-
creased mortality, mainly due to infections, cardiovascu-
lar events and malignant lymphoma [1]. Early diagnosis
and treatment with synthetic and biological disease-
modifying anti-rheumatic drugs (DMARDs) is crucial* Correspondence: eugen.feist@charite.de
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this article, unless otherwise stated.for remission of RA [2]. Since its authorization in 2006,
biological treatment with rituximab (RTX) was approved
in cases of inadequate response to tumor necrosis
factor-alpha inhibitors (TNFi) [3]. Due to its beneficial
safety profile and cost-efficacy, RTX has been currently
recommended as the first-line biologic treatment in
many countries worldwide [4]. Nevertheless, up to one
third of RA patients still fail to respond to biologics, in-
cluding RTX, leading to an individual as well as medical
and economic burden [5]. Therefore, to facilitate a more
personalized medicine, predictive biomarkers for re-
sponse are urgently needed.article is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
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usually evaluated by clinical and laboratory signs (cellular
and humoral parameters) [6–8]. Due to the mode of
action of RTX, follow-up investigations on cellular subsets
and humoral factors were of special interest reflecting
clinical response to RTX [9]. RA-associated autoanti-
bodies, like rheumatoid factor (RF) and anti-citrullinated
protein antibodies (ACPAs), were shown to be of predict-
ive value for response to RTX [6, 10, 11]. In this context,
RF showed treatment-related reductions, whereas anti-
bodies against cyclic citrullinated peptide (ACCP)
remained rather stable over the course of treatment
[12, 13]. Of note, ACPA-seropositivity includes heteroge-
neous fine specificities against diverse citrullinated pro-
teins [14]. Antibodies against MCV (AMCV) were shown
to be highly sensitive and to correlate with disease activity
of RA, probably due to the synovial appearance of the anti-
gen during inflammation [15–18]. In particular, a concomi-
tant presence of immunoglobulin (Ig) A with IgG AMCV
was associated with a severe disease course, suggesting pre-
dictive properties of AMCV isotypes [19]. AMCV positivity
was also postulated to predict (moderate) RTX response,Fig. 1 MCV epitope mapping in responders to RTX. The pattern of recogni
responders (n = 23) were reduced from baseline (a) to 24 weeks (b) after R
of positive patients)but AMCV kinetics, especially of isotypes under B-cell de-
pletion therapy (BCDT), have not been studied in greater
detail so far [6]. Although seropositivity of autoantibodies
seems to be a positive predictor for response to BCDT,
some seropositive patients respond to biological treatment
insufficiently.
An objective of this study was to differentiate sub-
groups of seropositive patients for response to RTX. For
this purpose, we investigated the epitope recognition
patterns against MCV and the AMCV isotypes in
AMCV IgG-positive patients with RA, in relation to
their therapeutic outcome to RTX. The aim was to de-
termine a predictive and monitoring parameter for RTX
treatment, and to gain further insights into the differen-




Our cohort was comprised of AMCV IgG-seropositive
RA patients (n = 50) fulfilling the new ACR/EULAR clas-
sification criteria [20], who were recruited from the out-zed MCV epitopes by IgG anti-MCV antibodies (AMCV) of RTX
TX treatment (x axis: wells A to H; y axis: wells 1 to 12; z axis: number
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Charité-Universitätsmedizin Berlin, Germany (n = 37),
and from the Federal Almazov Heart, Blood and Endo-
crinology Centre, St Petersburg, Russia (n = 13). Patients’
characteristics are summarized in Additional file 1. All
patients were inadequate responders to conventional
DMARDs, including methotrexate (MTX). RTX was ap-
plied in 30 patients as a second-line biologic after failure
to TNFi-treatment. A total of 20 patients were biologically
naïve and received RTX as a first-line biologic. Before
RTX application, all patients had active diseases despite
stable treatment with MTX (10 to 25 mg/week), as de-
fined by 28-joint Disease Activity Score based on erythro-
cyte sedimentation rate (DAS28-ESR) >3.2. The first cycle
of RTX (1,000 mg on days one and 15) was administered
after standard premedication, and patients were followed
up on for a period of six months. A good EULAR re-
sponse to RTX treatment was evaluated by DAS28-ESR
and defined as an improvement of ≥1.2 from baseline
to end of follow-up period [21], identifying 37 (74 %)
responders to RTX (RRs) and 13 (26-%) non-responders
to RTX (NRRs). RRs showed a higher DAS28 at baselineFig. 2 MCV epitope mapping in non-responders to RTX. The pattern of rec
non-responders (n = 11) remained stable or even expanded from baseline
wells 1 to 12; z axis: number of positive patients)compared to NRRs (6.23 versus 5.09). After the first RTX
cycle, DAS28 was significantly reduced in RRs compared
to NRRs (3.30 versus 4.72). However, according to EULAR
response criteria [22], only a minority of RRs achieved
either remission or low disease activity state at week 24
(see Additional file 1). After subsequent cycles of RTX, a
further improvement in DAS28 was observed in RRs (data
not shown). The study was approved by the local Ethics
Committees at the Charité-Universitätsmedizin Berlin,
Germany (vote EA1/193/10 april 26, 2012), and the
Federal Almazov Heart, Blood and Endocrinology Centre,
St. Petersburg, Russia (vote №124 may 21, 2012), and
informed consent was given by all patients prior to serum
sampling.
Methods
Anti-MCV reactivities in RRs and NRRs were investi-
gated by an MCV epitope mapping of AMCV IgG, and
by determination of AMCV isotype profiles in both
groups at baseline and after 24 weeks of RTX-treatment.
From the patients in our cohort, the antibody reactiv-
ities of 34 AMCV IgG-positive RA patients (23 RRsognized MCV epitopes by IgG anti-MCV antibodies (AMCV) of RTX
(a) to 24 weeks (b) after RTX treatment (x axis: wells A to H; y axis:
Table 1 Baseline and follow-up characteristics of anti-MCV isotypes for responders compared to non-responders to RTX treatment,
respecting baseline seropositivity, mean titers and relative titer changes upon RTX treatment
50 RA patients upon RTX treatment RRs (n = 37) NRRs (n = 13)
AMCV IgG
Positive at baseline (n, %) 37 100 % 13 100 %
Negative at baseline (n, %) 0 0 % 0 0 %
Mean baseline titer (v ± SD in U/ml) 769.05 891.04 856.99 982.98
Titer decrease (n, %) 31 84 % 11 85 %
Titer increase (n, %) 6 16 % 1 7.5 %
Mean titer at 24 weeks (v ± SD in U/ml) 390.46 432.06 662.67 834.47
Percentage decline/Wilcoxon P value 49.22 % P <0.0001 22.68 % P = 0.02
Mann–Whitney U P value (24 weeks) P = 0.288
Seronormalization (n, %) 4 11 % 1 8 %
Seroconversion (n, %) 0 0 % 0 0 %
AMCV IgM
Positive at baseline (n, %) 16 43 % 9 69 %
Negative at baseline (n, %) 21 57 % 4 31 %
Mean baseline titer (v ± SD in U/ml) 39.97 94.43 106.06 147.25
Titer decrease (n, %) 33 89 % 8 62 %
Titer increase (n, %) 4 11 % 5 38 %
Mean titer at 24 weeks (v ± SD in U/ml) 10.41 10.84 39.80 48.62
Percentage decline/Wilcoxon P value 73.95 % P <0.0001 62.5 % P = 0.03
Mann–Whitney U P value (24 weeks) P = 0.0003
Seronormalization (n, %) 11 69 % 3 33 %
Seroconversion (n, %) 0 0 % 1 25 %
AMCV IgA
Positive at baseline (n, %) 12 32 % 9 69 %
Negative at baseline (n, %) 25 68 % 4 31 %
Mean baseline titer (v ± SD in U/ml) 90.14 240.85 182.51 483.40
Titer decrease (n, %) 32 87 % 9 69 %
Titer increase (n, %) 5 13 % 4 31 %
Mean titer at 24 weeks (v ± SD in U/ml) 29.84 89.06 218.57 513.17
Percentage decline/Wilcoxon P value 67 % P <0.0001 19.76 % P = 0.17
Mann–Whitney U P value (24 weeks) P = 0.007
Seronormalization (n, %) 5 42 % 2 22 %
Seroconversion (n, %) 0 0 % 0 0 %
AMCV, antibodies against mutated citrullinated vimentin; n, number of patients; NRRs, non-responders to RTX; RRs, responders to RTX; RTX, rituximab; SD, standard
deviation; v, value
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of MCV using enzyme-linked immunosorbent assay
(ELISA). Referring to the MCV sequence, 18-mer pep-
tides with 12 overlapping amino acid residues to the
adjacent peptide were generated (with the general structure
Biotin-SGSG-PEPTIDE-Amide, JPT Peptide Technologies
GmbH, Berlin, Germany). Mutations (from glycerine to
citrulline and serine to histidine) and citrullinations
(replacement of each arginine by citrulline) were inserted.
The resulting peptides were applied in ascending ordercorresponding to the wells of a microtiter plate (A1-H1
(peptide 1–8), A2-H2 (peptide 9–16), A3-H3 (peptide
17–24), A4-H4 (peptide 25–32), A5-H5 (peptide 33–40),
A6-H6 (peptide 41–48), A7-H7 (peptide 49–56), A8-H8
(peptide 57–64), A9-H9 (peptide 65–72), A10-H10 (pep-
tide 73–80), A11-H11 (peptide 81–88)) (Additional file 2).
Additional to the 88 peptides, biotinylated recombinant
MCV, protein A and rheumatoid factor antigen were used
as internal controls in a separate row of the microtiter
plate (results not shown). Microtiter plates covering the
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serum sample in a dilution of 1:100 (Orgentec Diagnos-
tika, Mainz; Germany and Medipan GmbH, Berlin/
Dahlewitz, Germany) and 1:101 (Generic Assays GmbH,
Berlin/Dahlewitz, Germany) in sample buffer (Phosphate-
buffered saline [PBS] + 0.1% Tween-20 [NaCl, 1.37 mM;
KCl 27 mM; Na2HPO4 100 mM; KH2PO4 18 mM; 0.1 %
Tween; pH 7.2], all chemicals from Sigma-Aldrich Chemie
GmbH, Taufkirchen, Germany) for 30 minutes. After a
washing step, peroxidase conjugated anti-human IgG was
added for 30 minutes. After a second washing step, the
enzyme- triggered reaction (Dianova GmbH, Hamburg,
Germany) was performed by an incubation with 3,3,5,5′-
tetra-methyl benzidine (TMB, Life Technologies GmbH,
Darmstadt, Germany) as peroxidase substrate for 15
minutes and terminated by H2SO4 (Sigma-Aldrich Chemie
GmbH, Taufkirchen, Germany) stop solution. Visualization
and quantification of reaction products was made by
absorbance detection at 450/620 nm. The cut-off level was
set at 300 mOD, following receiver operating characteristic
(ROC) analysis.
Immunoglobulin isotypes IgG, IgM and IgA against
MCV were measured before and 24 weeks after the first ap-
plication of RTX in an expanded cohort of 50 patients.
Additionally, antibody subtypes of RF IgG, IgA, IgM and
ACCP IgG were determined. Detection of all antibodies
and subtypes was performed using ELISA. AMCV IgG, IgA
and IgM were detected by ELISA (Orgentec Diagnostika,
Mainz, Germany) with a cut-off level of 20 U/ml (ROC
curve analysis for AMCV IgA test is shown in Additional
file 3). RF IgG, IgM and IgA were determined by ELISA
(Generic Assays GmbH, Dahlewitz/Berlin, Germany) with a
cut-off level for RF IgG and IgA of 30 IU/ml, and 15 IU/ml
for IgM. ACCP IgG (second-generation assay) wasFig. 3 Baseline autoantibody profiles of responders and non-responders to
antibodies against MCV (AMCV) than responders (red), whereas the antibod
citrullinated peptide was nearly similar in both groupsmeasured by ELISA (Medizym® anti-CCP, Medipan GmbH,
Dahlewitz/Berlin, Germany) with a cut-off level of 30 U/ml.
All tests were performed according to the manufacturers’
instructions.
Statistics
The comparison of antibody reactivities was performed by
non-parametric tests with GraphPad Prism 4 (GraphPad
Software, Inc., La Jolla, US). The Wilcoxon signed rank
test was applied to compare the autoantibody titer differ-
ence from baseline to week 24 for RRs and NRRs. In order
to compare the titers of RRs with NRRs for each autoanti-
body subtype, for differences at baseline and at week 24, we
used the Mann–Whitney U test. Furthermore, the fre-
quency distribution of seropositivity of antibody subtypes in
RRs and NRRs was tested by the chi-squared and Fisher’s
exact test. P values lower than 0.05 were considered to be
significant. For correlation analysis, Pearson coefficients
were calculated.
Results
Epitope recognition reactivities to mutated citrullinated
vimentin peptides of anti-mutated citrullinated vimentin
IgG in responders and non-responders to rituximab
treatment
In order to clarify whether AMCV IgG-positive RRs
(n = 23) and NRRs (n = 11) to RTX differ in their
AMCV reactivities, we performed an epitope mapping
using overlapping MCV peptides that were recognized
by AMCV IgG of the patients. An illustration of the rec-
ognition pattern is shown for RRs (Fig. 1) and NRRs
(Fig. 2) as they were targeted on the microtiter plate
(x axis: wells A to H; y axis: wells 1 to 12; z axis: number
of positive patients). At baseline, only minor differencesRTX. Non-responders (blue) more frequently showed IgA and IgM
y distribution of rheumatoid factor (RF) and antibodies against cyclic
Table 2 Baseline and follow-up characteristics of rheumatoid factor and antibodies against CCP isotypes for responders and
non-responders to RTX, respecting baseline seropositivity, mean titers and their relative changes upon RTX treatment
50 RA patients upon RTX treatment RRs (n = 37) NRRs (n = 13)
RF IgG
Positive at baseline (n, %) 2 5 % 1 8 %
Negative at baseline (n, %) 35 95 % 12 92 %
Mean baseline titer (v ± SD in IU/ml) 11.99 15.99 13.69 12.30
Titer decrease (n, %) 37 100 % 13 100 %
Titer increase (n, %) 0 0 % 0 0 %
Mean titer at 24 weeks (v ± SD in IU/ml) 3.07 0.97 4.47 3.48
Percentage decline/Wilcoxon P value 74.38 % P <0.0001 67.32 % P = 0.002
Mann–Whitney U P value (24 weeks) P = 0.224
Seronormalization (n, %) 2 100 % 1 100 %
Seroconversion (n, %) 0 0 % 0 0 %
RF IgM
Positive at baseline (n, %) 21 57 % 8 62 %
Negative at baseline (n, %) 16 43 % 5 38 %
Mean baseline titer (v ± SD in IU/ml) 44.48 69.40 86.22 102.8
Titer decrease (n, %) 36 97 % 11 85 %
Titer increase (n, %) 0 0 % 2 15 %
Mean titer at 24 weeks (v ± SD in IU/ml) 16.54 20.85 58.67 81.14
Percentage decline/Wilcoxon P value 62.82 % P <0.0001 31.95 % P = 0.011
Mann–Whitney U P value (24 weeks) P = 0.170
Seronormalization (n, %) 8 38 % 1 13 %
Seroconversion (n, %) 0 0 % 0 0 %
RF IgA
Positive at baseline (n, %) 20 54 % 9 69 %
Negative at baseline (n, %) 17 46 % 4 31 %
Mean baseline titer (v ± SD in IU/ml) 102.35 124.7 167.6 144.7
Titer decrease (n, %) 30 81 % 10 77 %
Titer increase (n, %) 5 14 % 2 15 %
Mean titer at 24 weeks (v ± SD in IU/ml) 60.77 94.57 124.0 128.4
Percentage decline/Wilcoxon P value 40.62 % P <0.0001 26.05 % P = 0.014
Mann–Whitney U P value (24 weeks) P = 0.147
Seronormalization (n, %) 7 35 % 1 11 %
Seroconversion (n, %) 1 6 % 0 0 %
ACCP IgG
Positive at baseline (n, %) 34 92 % 12 92 %
Negative at baseline (n, %) 3 8 % 1 8 %
Mean baseline titer (v ± SD in U/ml) 1125.71 700.0 1044.35 775.6
Titer decrease (n, %) 29 78 % 8 62 %
Titer increase (n, %) 5 14 % 4 31 %
Mean titer at 24 weeks (v ± SD in U/ml) 841.11 667.2 861.55 682.1
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Table 2 Baseline and follow-up characteristics of rheumatoid factor and antibodies against CCP isotypes for responders and
non-responders to RTX, respecting baseline seropositivity, mean titers and their relative changes upon RTX treatment (Continued)
Percentage decline/Wilcoxon P value 25.28 % P <0.0001 17.50 % P = 0.129
Mann–Whitney U P value (24 weeks) P = 0.982
Seronormalization (n, %) 0 0 % 0 0 %
Seroconversion (n, %) 0 0 % 0 0 %
ACCP, antibodies against cyclic citrullinated peptide; n, number of patients; NRRs, non-responders to RTX; RF, rheumatoid factor; RRs responders to RTX; RTX, rituximab;
SD, standard deviation; v, value
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body reactivity against several sequences of the MCV pro-
tein with few predominant epitopes (A4, A5, C5 and D5)
could be observed. After RTX treatment, differences be-
tween RRs and NRRs became more apparent: 69.6 % (16Fig. 4 Autoantibody isotype-related mean titer change of responders (RRs)
IgM and especially IgA antibodies against MCV (AMCV) were significantly d
months. Changes in RF isotypes and antibodies against CCP (ACCP) showeout of 23) of the RRs and only 27.3 % (three out of 11) of
the NRRs showed a reduction of their initial recognition
pattern. Moreover, epitope recognition in 45.4 % (five out
of 11) of NRRs remained unchanged, and expanded in
27.3 % ( three out of 11).and non-responders (NRRs) upon RTX -treatment. Mean titer course of
ifferent in RRs and NRRs to RTX, with higher reductions in RRs after six
d no significant difference between groups
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baseline in responders and non-responders to rituximab
In order to clarify whether the response outcome among
seropositive patients is associated with Ig isotypes, we ana-
lyzed the qualitative distribution of IgM and IgA in
AMCV IgG-positive patients and compared them with
isotypes of RF and ACCP IgG. At baseline, a lower preva-
lence of AMCV subtypes was observed in RRs compared
to NRRs, with significant differences for AMCV IgA
(Table 1 and Fig. 3). In detail, one third (12 out of 37) of
the RRs were positive for AMCV IgA titer, whereas 69 %
(9/13) of the NRRs were seropositive at baseline (χ2
P = 0.0203). Being AMCV IgA-negative at baseline with
an isolated IgG response could indicate a better response
to RTX, (negative predictive value = 86.02 %). In return,
baseline double-positivity of IgA and IgG was predictiveFig. 5 Individual IgA anti-MCV titer courses of responders and non-respond
showed a greater tendency to reduce their initial titer from baseline to we
remained stablefor a poor response to RTX (positive predictive value =
42.86 %).
Similar but less significant findings were observed
for the qualitative difference of AMCV IgM in RRs
and NRRs (Table 1). RRs were also less frequently
AMCV IgM-positive at baseline compared to NRRs
(43 % versus 69 %), but this difference did not reach
statistical significance (χ2 P = 0.105). In contrast, IgG,
IgM and IgA subclasses of RF, as well as ACCP IgG,
showed nearly similar distributions in RRs and NRRs
without apparent differences at baseline (Table 2 and
Fig. 3).
Taken together, in our cohort RRs to RTX were char-
acterized by an isolated IgG AMCV response at baseline.
In return, co-existent AMCV IgA were able to indicate a
poorer response to RTX.ers upon RTX treatment with mean titer change (red). Responders
ek 24 upon RTX treatment compared to non-responders, who rather
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responders and non-responders upon rituximab treatment
For quantitative analysis, we determined the mean titer
courses of AMCV isotypes upon RTX treatment in RRs
and NRRs and compared them with RF subtypes and
ACCP IgG (Tables 1 and 2, Fig. 4). RRs showed lower
mean titers of all AMCV subtypes at baseline, with a
further substantial reduction upon treatment. In contrast,
NRRs exhibited higher AMCV titers at baseline, which
were less sensitive to change despite treatment (Fig. 4).
Most notably, the mean baseline AMCV IgA titer of RRs
decreased by nearly 67 % (from 90.14 to 29.84 U/ml;
P <0.0001), whereas the titer of NRRs was twice as high at
baseline and rather remained stable, with a non-significant
increase of 19.76 % during the follow-up period (from
182.51 to 218.57; P = 0.17) (Fig. 5). To evaluate a clear dif-
ference of AMCV IgA variations between RRs and NRRs
without bias of seronegative patients, we considered the
titer changes of AMCV IgA-positive RRs and NRRs. The
tendency became more obvious: a similar baseline titer in
RRs and NRRs (261.55 versus 259.99 U/ml) decreased sig-
nificantly in RRs by 69 % (to 81.56 U/ml; P = 0.0005), but
increased slightly in NRRs by 20 % (to 312.25 U/ml;
P = 0.2). As a result, the change of AMCV IgA in RRs was
significantly different compared to NRRs at the end of the
follow-up period (P = 0.007).
With respect to AMCV IgM, a titer decrease was ob-
served in both RRs and NRRs, but with an increased
decline in RRs (Table 1). In detail, AMCV IgM titers de-
creased significantly by 73.95 % in RRs (P <0.0001) and
by 62.5 % in NRRs (P = 0.03), with a substantialTable 3 Anti-MCV IgA titer courses of responders and non-responde
months of RTX treatment (according to the EULAR response criteria)
Responders to RTX (RRs)
DAS28 response of 37 RRs at week 24
(number of RRs)
mean AMCV IgA titer at
baseline (U/ml)
DAS28 ≤2.6 remission (12/37) 141.94
DAS28 ≤3.2 and >2.6 low disease
activity (5/37)
33.85
DAS28 ≤5.1 and >3.2 moderate disease
activity (17/37)
83.52
DAS28 >5.1 high disease activity (3/37) 14.32
Non-responders to RTX (NRRs)
DAS28 response of 13 NRRs at week 24
(number of NRRs)
mean AMCV IgA titer at
baseline (U/ml)
DAS28 ≤2.6 remission (0/13) /
DAS28 ≤3.2 and>2.6 low disease
activity (1/13)
46.11
DAS28 ≤5.1 and >3.2 moderate disease
activity (7/13)
290.79
DAS28 >5.1 high disease activity (5/13) 71.41
AMCV, antibodies against mutated citrullinated vimentin; DAS28, 28-joint Disease Activ
RTX; RRs, responders to RTX; RTX, rituximabdifference between both groups at week 24 (P = 0.0003)
(Fig. 4). More seropositive RRs normalized their titer
levels for AMCV IgM and AMCV IgA under the cut-off
level than NRRs after treatment. The number of patients
who normalized their AMCV IgA levels was less fre-
quent compared to AMCV IgM.
Such autoantibody kinetics were not observed for RF
subtypes and ACCP IgG (Table 2). Although the mean
baseline titers of RF IgG, IgM and IgA (with the excep-
tion of ACCP IgG in NRRs) decreased significantly with
treatment in RRs and NRRs (P <0.0001), the difference
did not reach statistical significance at week 24 (Mann–
Whitney U P >0.05) (Fig. 4).
IgA anti-mutated citrullinated vimentin titers in relation
to Disease Activity Score 28 treatment response
AMCV IgA titer reductions reflected improved treatment
response according to the DAS28 and the EULAR response
criteria (Table 3). In detail, RRs who achieved remission at
week 24 had the greatest percentage reductions in AMCV
IgA titers, RRs with low and moderate disease activity pre-
sented moderate decreases and RRs with high disease activ-
ity revealed only a minor decline in AMCV IgA titers
(Fig. 6). In comparison, NRRs with moderate disease activ-
ity at week 24 had rather unchanged AMCV IgA titers
over time and NRRs with high disease activity even
showed an increase of AMCV IgA titers (Fig. 6). Interest-
ingly, the absolute titer exerted no influence. Thus, only
the relative change of AMCV IgA titers from baseline to
the end of the follow-up period provides information
about the response characteristic.rs to RTX in relation to their achieved DAS28 response after six




30.00 78.86 % (111.93)
17.06 49.61 % (16.79)
37.26 55.39 % (46.26)
8.45 41.00 % (8.87)





55.56 17.01 % (9.45)
270.51 06.97 % (20.27)
221.49 67.76 % (150.08)
ity Score; EULAR, European League against Rheumatism; NRRs, non-responders to
Fig. 6 Mean IgA anti-MCV titer course for responders and non-responders to RTX corresponding to their achieved Disease Activity Score 28 (DAS28)
after RTX treatment. The achieved DAS28 and treatment response at week 24 according to the EULAR response criteria were reflected by the extent of
anti-MCV IgA titer reductions. The better the DAS28 responses were, the greater the IgA anti-MCV reductions were. Responders in remission showed
the greatest IgA anti-MCV reductions, whereas non-responders with high disease activity slightly increased their initial levels. EULAR, European League
against Rheumatism; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity
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AMCV IgA and DAS28 could be described (Fig. 7). In
order to determine a purely quantitative relation be-
tween AMCV IgA and DAS28 without bias of two dif-
ferent time points, we correlated the difference from
baseline to the end of the follow-up period in titers of
AMCV IgA-positive patients (n = 21) in relation to their
change in DAS28. A correlation coefficient of r = 0.49
was found (P = 0.023). The greater the difference and re-
duction of AMCV IgA titers were, the greater the dif-
ference and improvement in DAS28 were. This was in
agreement with the above-mentioned AMCV IgA reduc-
tions in relation to their DAS28 response. In contrast,
no significant correlation was observed for the other
autoantibody subtypes and DAS28 values (data not
shown).Coincidence of autoantibody subtypes in IgA antibody
against mutated citrullinated vimentin-positive patients
Interestingly, in our AMCV IgG-positive cohort, almost
all patients were also positive for ACCP IgG (n = 46 out
of 50) but negative for RF IgG (n = 47 out of 50) (Tables 1
and 2). A separation into AMCV IgA-positive (n = 21)
versus AMCV IgA-negative (n = 29) patients revealed a
higher association of the other AMCV subtypes, with con-
sequent higher mean titers of IgM and IgG in the AMCV
IgA-positive group (Table 4). In detail, AMCV IgG titers
were twofold and IgM titers threefold higher in the
AMCV IgA-positive group compared to the negative
group (P = 0.012). Furthermore, only the subtype IgA of
RF showed a significant coincidence with AMCV IgA.
ACCP IgG and RF IgM were not significantly associated
with AMCV IgA (P <0.05) (Fig. 8).
Table 4 Coincidence of autoantibody subtypes with anti-MCV IgA (AMCV IgA)-positive and -negative patients respecting seropositivity
and mean titers at baseline
AMCV IgA-positive patients AMCV IgA-negative patients Mann–Whitney U
P value(n = 21) (n = 29)
AMCV IgG positive (%, n) 100 % (21/21) 100 % (29/29)
negative (%, n) 0 0
mean titer (U/ml) 1128.58 548.13 0.012
SD (U/ml) 1160.25 573.98
AMCV IgM positive (%, n) 71 % (15/21) 34 % (10/29)
negative (%, n) 29 % (6/21) 66 % (19/29)
mean titer (U/ml) 98.65 27.1 0.005
SD (U/ml) 157.69 47.63
RF IgG positive (%, n) 10 % (2/21) 3 % (1/29)
negative (%, n) 90 % (19/21) 97 % (28/29)
mean titer (IU/ml) 16.42 9.54 0.013
SD (IU/ml) 15.62 14.13
RF IgM positive (%, n) 71 % (15/21) 48 % (14/29)
negative (%, n) 29 % (6/21) 52 % (15/29)
mean titer (IU/ml) 83.47 34.96 0.071
SD (IU/ml) 103.29 51.77
RF IgA positive (%, n) 81 % (17/21) 41 % (12/29)
negative (%, n) 19 % (4/21) 59 % (17/29)
mean titer (IU/ml) 161.68 88.66 0.003
SD (IU/ml) 137.91 120.54
ACCP IgG positive (%, n) 100 % (21/21) 86 % (25/29)
negative (%, n) 0 % (0/21) 14 % (4/29)
mean titer (U/ml) 1262.77 989.99 0.253
SD (U/ml) 597.03 776.62
ACCP, antibodies against cyclic citrullinated peptide; AMCV, antibodies against mutated citrullinated vimentin; n, number of patients; NRRs, non-responders to
RTX; RF, rheumatoid factor; RRs, responders to RTX; RTX, rituximab; SD, standard deviation
Fig. 7 Correlation of IgA anti-MCV and Disease Activity Score 28 (DAS28) in IgA anti-MCV-positive patients. The difference (delta) of anti-MCV IgA
titers (delta anti-MCV IgA) from baseline to 24 weeks after RTX treatment correlated moderately with a greater improvement of DAS28 (delta
DAS28) in anti-MCV IgA-positive patients (n = 21) (r = 0.49)
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Fig. 8 Coincidence of autoantibody subtypes with anti-MCV (AMCV) IgA-positive and -negative patients at baseline. AMCV IgA-positive patients
(purple) showed a greater overlap with RA-associated autoantibodies than AMCV IgA-negative patients (green), with significant coincidence of
AMCV IgA, IgM and RF IgA
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The objective of this study was to identify a predictive
biomarker among RA patients undergoing BCDT with
RTX. Since seropositivity for RA-associated autoanti-
bodies are accepted indicators for response to RTX, we
investigated whether differences in fine reactivity and Ig
isotype kinetics among AMCV-positive patients could
provide additional information. Since the pathogenetic
role of these immunoglobulin isotypes is also of interest,
we compared the profile of AMCV antibodies to estab-
lished RF subtypes and ACCP IgG.
Analysis of AMCV IgG-positive patients revealed dif-
ferences with respect to MCV epitope recognition pat-
terns, serological baseline status and follow-up changes
in relation to response outcome. Patients with response
to RTX were characterized by a restrictive antibody
response of AMCV IgG, decreasing mean titers and
reduction of initially recognized epitope pattern upon
treatment. In contrast, double-seropositivity for AMCV
IgG and IgA (and IgM, but to a lesser degree), stable
antibody mean titers and an unchanged or even ex-
panded epitope recognition pattern during the follow-up
period were associated with non-response to RTX. These
findings were confirmed by a moderate correlation of
AMCV IgA reductions with improved DAS28 response.
In general, non-response to RTX could be due to resis-
tant B-cell repertoire or/and pharmacokinetic differences
in individual cases, like different tissue penetration of RTX
to lymphoid niches [23]. In this context, the results of our
study provide evidence for a RTX-sensitive B-cell subpop-
ulation in RRs with a reduced epitope recognition pattern
and decreasing IgG titers under treatment. In contrast, an
unchanged or even expanded reactivity after B-cell deple-
tion could be explained by active IgG-producing B-cell
subsets in NRRs, which are less sensitive to RTX. Further-
more, a higher coincidence of AMCV isotypes, includingIgA, in NRRs could be related to refractory IgA-producing
B-cell subsets.
A close link of RTX response to CD20-positive mem-
ory B-cell compartment has been shown by previous
studies. In most of these investigations, NRRs had an in-
complete depletion and higher repopulation numbers of
memory B-cells [24–26]. These memory B-cells are in-
volved in the formation of secondary germinal centers
and differentiate into CD20-negative plasmablasts and
plasma cells, contributing to active inflammatory re-
sponses with rise in antibody levels [27]. Both isotypes
IgA and IgG are mainly produced by tissue-resident
memory B-cells and plasma cells [28, 29]. Since the dis-
tribution and architecture of these compartments can
vary between individuals, RTX can cause distinct deple-
tion of these B-cells with individually varying IgA or IgG
kinetics [30]. In this context, stable AMCV IgA titers in
both RRs and NRRs could be explained by lower sen-
sitivity of AMCV IgA-producing B-cells towards RTX
treatment. As shown also by vaccination studies, BCDT
affects mainly short-lived CD20-positive B-cells, explain-
ing especially the decline of IgM titers, which was also
observed in our cohort [31].
The association of non-response to RTX with the appear-
ance of IgA anti-MCV points to the significance of this Ig
subset in RA. At early stages of RA investigations, the pres-
ence of IgA RF was shown to be associated with increased
disease activity and severity [32]. Furthermore, IgA RF also
preceded disease onset and was linked to extraarticular
manifestations and resistance to treatment with TNFi
[33, 34]. Of note, overall serum IgA and IgG levels have
been described as rather stable, even after repeated cycles
of RTX in RA patients [35]. Finally, co-expression of IgA
and IgG for AMCV has been associated with disease sever-
ity by another prior study [19], which supports the rele-
vance of an interaction between the mucosal and systemic
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serum IgA from circulating plasmablasts and suggested
their origin to be from mucosal memory B-cells [36]. Due
to loss of CD20 receptors, these mucosal plasmablasts were
not depleted by RTX [37], and subsequently, levels of IgA
remained stable. As known from vaccination studies, IgA
responses were mainly induced by oral but not systemic ex-
posure to antigen within the mucosa-associated lymphoid
tissues [38]. Thus, the appearance of IgA autoantibodies
suggests primarily mucosal triggers for such autoimmune
responses. This connection of mucosal immune reactions
and autoimmune disorders is also supported by known oral
or gastrointestinal triggers in RA [39, 40], including
nutrition-dependent increase in antibody titers [41]. In
summary, it can be hypothesized that tissue-resident mem-
ory B-cells could represent the main source for such plas-
mablasts, causing treatment resistance to RTX.
Our study is limited by the relatively small sample size
and inclusion of patients from two cohorts, of whom
one part received RTX as a first-line biologic. Thus, dif-
ferent pretreatment with biologicals and concomitant
medication could have influenced our results. Further-
more, by preselecting for AMCV IgG-positive patients,
we could have missed different subtype kinetics in other
serologic subgroups. Although this study design limits
the comparability to existing studies, we were able to
perform detailed analyses of the autoantibody kinetics in
RTX-treated patients. In summary, our results confirm a
correlation of AMCV subtypes with disease activity, and
provide evidence for their potential prediction and mon-
itoring value.
Conclusions
Restrictive baseline seropositivity for anti-MCV IgG
was identified as a predictor for response to RTX. Co-
expression of IgA was associated with treatment failure to
RTX. Reduction of AMCV IgA titers under RTX showed
a correlation with EULAR response in RA. Furthermore,
rigid IgA isotype under such targeted therapies could be
related to refractory B-cell subsets, giving evidence of
greater heterogeneity within the so called seropositive RA
cohort.
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